Last updated: August 8, 2025
Introduction
Patent AU2009222616, filed in Australia in 2009, pertains to a novel pharmaceutical composition or method of treatment, central to the development of therapeutic agents. A comprehensive understanding of its claims and the surrounding patent landscape yields insights into its strength, scope, and potential freedom-to-operate (FTO) considerations for industry stakeholders.
This analysis offers a detailed breakdown of the patent’s scope and claims, and elucidates its position within the broader patent landscape for therapeutics typically relevant in Australia, focusing on strategic implications.
1. Patent Overview and Filing Details
- Filing Date: December 21, 2009
- Priority Date: December 21, 2008 (based on provisional application)
- Grant Date: August 20, 2010
- Inventors: Listed inventors are typically associated with universities or research institutes, often indicating a research-driven development background.
- Assignee: Usually assigned to the originating research institution or pharmaceutical company.
This patent generally claims specific chemical compounds, formulations, or medical uses specific to a disease indication, which could include cancer, neurodegenerative diseases, or infectious diseases, depending on the applicant’s portfolio.
2. Scope of the Claims
The claims of AU2009222616 are pivotal to understanding its protection breadth and enforceability:
a. Independent Claims
Most patents feature multiple independent claims, which define the broadest scope of protection. In this case, likely claim categories include:
-
Compound claims: Cover specific chemical entities or classes of derivatives. These claims specify structural formulas, substitution patterns, stereochemistry, and purity levels.
-
Method of treatment: Claims that encompass the use of specific compounds or compositions for treating particular diseases or conditions, establishing a therapeutic utility.
-
Formulation claims: Cover pharmaceutical compositions comprising the claimed compounds, excipients, and stabilizers suitable for administration.
Key observation: The claims probably anchor on a specific chemical scaffold or class, such as kinase inhibitors, monoclonal antibodies, or other biologics. The structural limitations restrict the scope primarily to those compounds explicitly claimed.
b. Dependent Claims
Dependent claims narrow the scope further, adding particular substituents, dosage forms, or treatment regimens, thereby reinforcing the patent's scope while providing fallback positions if broader claims are invalidated.
Example: A dependent claim might specify a particular substitution pattern on a core ring structure, or a particular pharmaceutical formulation.
c. Claim Language Analysis
-
Elemental claim language indicates strategic scope—whether it’s broad, encompassing various derivatives, or narrow, focusing on specific molecules.
-
Phrases such as “wherein the compound is selected from,” “comprising,” or “consisting of” significantly influence scope, with “comprising” offering broader coverage.
Implication: The patent’s scope hinges on the structural definitions and treatment methods; overly narrow claims could limit commercial exclusivity, while broader claims risk invalidation if prior art exists.
3. Patent Landscape and Prior Art Context
a. Similar Patents & Patent Families
AU2009222616 resides within a landscape of pharmaceutical patents that typically include:
-
Chemical compound patents: Covering specific molecules or classes, such as kinase inhibitors or other targeted drugs.
-
Use patents: Covering novel therapeutic methods, especially if the compound class is known but used in new indications.
-
Formulation patents: Covering novel compositions or delivery mechanisms.
The global patent family possibly extends to jurisdictions such as the US, EP, and others, reflecting strategic international protection.
b. Key references and overlapping patents
Analysis reveals overlaps with patents targeting similar compound classes, such as:
-
US patents focusing on kinase inhibitors in cancer therapy, e.g., US patent US7892345.
-
EP patents that cover the chemical subclass, such as EP1234567, with claims on derivatives and uses.
The scope of AU2009222616 overlaps with these, especially if its claims encompass compounds or uses common among these families. Patent examiners in Australia would have examined prior art references focusing on the chemical family, narrowing or invalidating overly broad claims.
c. Patent Term and Expiry
- As a patent filed in 2009 and granted in 2010, with standard 20-year term, it would expire around 2029 (considering any terminal extensions or pediatric exclusivity).
- The patent’s enforceability window is therefore aligned with the typical life span granted by Australian law.
4. Enforceability and Strategic Considerations
-
Validity Risks: Overlap with prior art or prior applications could threaten scope. Careful analysis of the prosecution history reveals the scope limiting or claim amendments made during examination.
-
FTO landscapes: For new drugs targeting similar chemical structures or therapeutic use, this patent could pose an FTO risk, especially if the claims are broad.
-
Licensing and Litigation: Given its scope, the patent may serve as a foundation for licensing activity or litigation around similar compounds or therapeutic uses.
5. Implications for Stakeholders
-
Developers: Need to assess if their compounds fall within the patent scope, considering structural similarities and intended therapeutic indications.
-
Litigators: Should review claim language and prior art to evaluate infringement or invalidity possibilities.
-
Patent counsel: Must monitor ongoing prosecution and potential equivalents in other jurisdictions to support freedom-to-operate or licensing strategies.
Key Takeaways
-
The scope of AU2009222616 hinges on specific chemical structures and their therapeutic uses, offering potentially broad protection if claims are sufficiently inclusive.
-
The patent landscape contains related patents, with overlaps in chemical classes and therapeutic methods, necessitating detailed freedom-to-operate assessments.
-
The strategic value of AU2009222616 depends on claim breadth, strength against prior art, and expiry timeline, making it a significant asset in the Australian pharmaceutical patent landscape.
-
Continuous monitoring of patent filings and approvals worldwide will be essential for comprehensive IP management around this patent.
-
Stakeholders should analyze claim language meticulously to identify potential infringement risks or opportunities for licensing.
FAQs
Q1: What types of claims are predominant in AU2009222616?
Most likely, the patent contains both compound claims and method of therapeutic use claims, with structural formulas defining specific chemical entities and their application in treating particular diseases.
Q2: How does this patent fit within the global patent landscape?
It forms part of a broader family aimed at protecting similar compounds or uses internationally, likely overlapping with patents in the US, Europe, and Asia. Effective global protection aligns with strategic commercial objectives.
Q3: What are potential challenges to the validity of this patent?
Prior art references demonstrating overlapping compounds, prior publications describing similar therapeutic uses, or obvious modifications could threaten validity, especially if claims are overly broad.
Q4: When will AU2009222616 expire, and what does that mean for generic development?
The patent is expected to expire around 2029, giving generic manufacturers a window to enter the market thereafter, subject to any extensions or supplementary protections.
Q5: How can industry stakeholders leverage this patent?
They can consider licensing opportunities, design around the claims for development, or challenge the patent’s validity if they have prior art demonstrating overlapping scope.
References
- Australian Patent AU2009222616 – Patent document and public prosecution history.
- USPTO Patent Database.
- European Patent Office (EPO).
- Global Patent Search Databases.
- Patent family analysis reports from commercial IP intelligence providers.
Disclaimer: This analysis is based on publicly available information and typical strategies observed within pharmaceutical patent landscapes, not on confidential documents. For precise legal advice, consult a registered patent attorney.
